We are member of the ADITEC Consortium, a collaborative research programme that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 13 countries and 42 research partners collaborate in the Aditec project.
Aditec comprises some of the most competitive European research groups from universities, research institutions and biotech companies together with top US groups on systems biology and adjuvants. Different aspects of vaccination, from basic research, new technologies to clinical trials and public health, are covered.
Aditec started in October 2011, is a 6-year project and has received funding from the European Union’s Seventh Programme for research, technological development and demonstration under grant agreement No280873.
Analysis of DC involvement in the induction of immune responses by Integrase-Defective Lentiviral Vectors (IDLV)
Recent reports highlight the potential for integrase-defective lentiviral vectors (IDLV) to be developed as vaccines due to their ability to elicit cell-mediated and humoral immune responses after intramuscular administration. This vector induces strong and long lasting immune responses. In the context of ADITEC, to decipher the mechanisms of induction of strong immune responses by IDLV, we are currently analyzing, in collaboration with A. Cara et D. Negri (Istituto Superiore di Sanità, Roma, Italy), the involvement of DC subsets in the induction of both innate and adaptive responses by IDLV using pDC and cDC deficient mice.